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Abstract 
Bronchiectasis is an acquired irreversible bronchopulmonary disease where 
bronchial walls in the lungs are permanently inflamed and dilated. This leads to a 
‘vicious cycle’ between chronic bacterial infection and immune dysregulation. One of 
the bacterial infections patients with bronchiectasis experience is S. maltophilia, a 
Gram-negative gamma proteobacteria with intrinsic multidrug resistance and widely 
found in the environment. S. maltophilia is also a common infection in CF patients 
but has poorly been characterised in bronchiectasis. This study looks at its 
significance in bronchiectasis and tries to establish a comparison between 
environmental and clinical strains as well as to elucidate the question of its 
pathogenicity which is still controversial.   
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Bronchiectasis is an acquired irreversible bronchopulmonary disease where the 
bronchial wall in the lungs is permanently inflamed and dilated  (José and Brown, 
2014). This leads to what is sometimes referred to as a ‘vicious cycle’ (Cole, 1986) 
between chronic bacterial infection and immune dysregulation (Fig. 1.1): the 
damaged function of the bronchi results in an accumulation of mucus in the lungs 
which is conducive to bacterial infections which, in turn, cause further damage to the 
bronchial wall of the lung by eliciting an inflammatory response and further debilitate 
the mucociliary apparatus which loses its ability to properly clear mucus from the 
lungs (Boyton, 2012).  
 
Figure 1.1 The vicious cycle of inflammation and infection in bronchiectasis  
(adapted from José and Brown, 2014). 
 
1.1.1. Aetiology of bronchiectasis 
Many cases of bronchiectasis arise without any known cause and are referred to as 
idiopathic. However, when a cause is found, the most common aetiology is past 




 Findings from several epidemiology studies demonstrated that some specific ethnic 
populations have a significantly higher incidence of bronchiectasis than others: for 
example, a study cohort from central Australia showed a 40-fold increase in the rate 
of bronchiectasis among Aboriginal children compared to the rate of their non-
Indigenous counterparts (Chang et al., 2002). This evidence suggests that risk 
populations may also have underlying immuno-genetics predisposing them for the 
disorder.  
1.1.2. Clinical features and diagnosis 
The main clinical features that can help detection of bronchiectasis are chronic 
cough, production of sputum and persistent bacterial infection although some 
patients presenting mild forms of the disease can be asymptomatic (Boyton et al., 
2013). Those symptoms also overlap with other pulmonary diseases with a higher 
incidence than bronchiectasis such as asthma, tracheobronchial infection and 
chronic obstructive pulmonary disease (COPD) which make it difficult to diagnose 
(Hacken and van der Molen, 2010). High resolution computed tomography (HRCT) 
of the chest (Figure 1.2) is currently the gold standard for diagnosis (Boyton, 2012).  
Following the HRCT, a score ranging from 1-18 is attributed to the patient 
depending on the number of lobes affected and their degree of dilatation (Chalmers 
et al., 2014). With the widespread use of CT scans, figures for incidence of 
bronchiectasis per year are on the increase in recent years, suggesting it might have 
been significantly underdiagnosed in the past (King, 2011). In the United Kingdom, 
for instance, it is estimated that over 1 in 1000 people currently live with 
bronchiectasis (Hill, 2012) and a recent cohort study from the UK found that 
incidence of bronchiectasis in women had increased from 21.2 to 35.2 and in men 
from 18.2 to 26.9 per 100 000 per person-years from 2004 to 2013 (Quint et al., 
2016).  
However, the scope of severity of the condition varies greatly between patients and 
the HRCT score does not provide an accurate way for assessing it as it misses 
many other factors that can also influence the severity. Hence, in addition to the 
radiological diagnosis by HRCT, clinicians use two scoring systems: the 
Bronchiectasis Severity Index (BSI) (Chalmers et al., 2014) and the FACED score 
(Martínez-García et al., 2014; Guan, Chen and Zhong, 2016).  
The BSI is an algorithm which was designed to comprehensively assess the severity 
of the condition for each patient and provide a prediction of future exacerbations and 
mortality (Chalmers et al., 2014) (Table 1.1). This takes into account the following 
parameters: age, BMI (Body Mass Index), spirometry values (% FEV1 predicted), 
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previous hospital admissions, exacerbation(s) frequency, presence of Pseudomonas 
aeruginosa or other bacteria, the radiological severity (i.e. number of lobes affected) 
and the medical research council (MRC) breathlessness score. An online calculator 
is available via the following website: http://www.bronchiectasisseverity.com/ where 
clinicians just need to insert the patient’s values for each of the parameters and the 
score is automatically calculated: a score between 0 and 4 corresponds to a mild 
form of bronchiectasis; a score between 5 and 8 suggests a moderate stage of 
bronchiectasis and finally, a score equal to or above 9 relates to severe cases of 
bronchiectasis (Chalmers et al., 2014).  
Table 1.1 Rates of mortality and hospitalisation over 1- and 4-years follow-up based on the 
bronchiectasis severity score (BSI) 
Severity Score range 
1 year 4 years 
Rate of mortality Rate of hospitalisation Rate of mortality Rate of hospitalisation 
Mild 0-4 0-2.8% 0-3.4% 0-5.3% 0-9.2% 
Moderate 5-8 0.8-4.8% 1.0-7.2% 4-11.3% 9.9-19.4% 
Severe >9 7.6-10.5% 16.7-52.6% 9.9-29.2% 41.2-80.4% 
 
On the other hand, the FACED score is a 7 points grading system taking into 
account five dichotomised parameters: the FEV1 score, the age, Pseudomonas 
aeruginosa chronic colonisation, the extent of bronchiectasis and the level of 
dyspnoea based on the Medical Research Council (MRC) scale (Table 1.2) and 
which provides a prediction of 5-year all-cause mortality rate for each severity 
category (Martínez-García et al., 2014). 
Table 1.2 Scoring system of the five dichotomised parameters included in the FACED score 
F FEV1  ≥ 50 % = 0 points < 50 % = 2 points 
A Age > 70 years = 0 points ≥ 70 years = 2 points 
C 
Chronic colonisation 
with P. aeruginosa 
No = 0 points Yes = 1 point 
E Extent of bronchiectasis 1-2 lobe(s) affected =1 point  2 lobes affected = 2 points 
D Dyspnoea MRC score 0-II = 0 points III-IV = 1 point 
TOTAL SCORE :                                                                      5-YEAR MORTALITY RATE : 
 0-2 points     MILD BRONCHIECTASIS                                           4% 
 3-4 points     MODERATE BRONCHIECTASIS                              25% 
 5-7 points     SEVERE BRONCHIECTASIS                                    56% 
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 This classification may allow for more personalised treatment and for deciding on 
the best treatment after evaluating the risk/benefit ratio (Chalmers et al., 2014).  
 
Figure 1.2 HRCT scan showing the main signs of bronchiectasis. A shows a bronchus 
terminating is a cyst; B shows the lack of bronchial tapering as it travels to the periphery of 
the lung; C shows the sign of a signet ring where the bronchus is larger than the 
accompanying vessel; D shows a mucus plug, completely blocking the airway lumen 
(McShane et al., 2013). 
 
1.1.3. Treatment and management 
Bronchiectasis is a progressive disease; its severity increases with time in patients 
with more advanced bronchiectasis. However, the aim with early detection is to slow 
down the progression and help manage the disease better so that, following an 
appropriate treatment plan, prognosis can be improved and life expectancy and 
quality of life (QoL) maintained (Hill, 2012).  
Due to the impaired mucociliary clearance function, the mainstay of bronchiectasis 
management is chest physiotherapy (Fig. 1.3): all patients, regardless of the severity 
of their condition are encouraged to learn and practice airway clearance techniques 
in order to facilitate sputum expectoration (Chalmers, Aliberti and Blasi, 2015). The 
most common techniques for doing so are active cycle breathing technique, 
autogenic drainage and the use of positive expiratory pressure devices (Snijders et 
al., 2015).   
To tackle bacterial colonisation and airway inflammation involved in bronchiectasis, 
the most common treatments consist of short- or long-term inhaled antibiotics, 
inhaled corticosteroids and macrolides (Fig 1.3).  
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Most commonly used macrolides are azithromycin (Wong et al., 2012) and 
erythromycin (Serisier et al., 2013; Chalmers et al., 2015). Recent studies provide 
evidence for their beneficial effects in bronchiectasis patients where they have been 
proven to significantly reduce the rate of exacerbations and a meta-analysis of 
randomised controlled trials (Fan et al., 2015) suggested that they improve the St 
George Respiratory Questionnaire (SGRQ) score –a disease-specific questionnaire 
on QoL of patients (Wilson et al., 1997). However, the use of macrolides has also 
been associated with important side-effects on the gastrointestinal and 
cardiovascular systems, increased antimicrobial resistance, potential risk of hearing 
loss and potential predisposition to environmental mycobacteria infection which can 
lead to macrolide resistance (Fan et al., 2015).   
On the other hand, the use of inhaled corticosteroids, regular high dose inhaled 
steroid treatment was shown to result in a reduced sputum volume and to decrease 
the amount of inflammatory markers found in sputum, also resulting in an 
improvement of QoL (SGRQ score).However, there is no clear evidence for 
improvement of patient’s lung function or rate of exacerbations and the BTS 
guidelines do not support the routine use of long-term inhaled corticosteroids (Goyal 
and Chang, 2014). Importantly, reported cases of adrenal suppression and 
increased risk of pneumonia in COPD patients associated with inhaled steroids 





Figure 1.3 Current recommended therapies for each of the elements of Cole’s vicious cycle 
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Finally, the advantage of inhaled antibiotics is their ability to deliver higher 
concentrations of antibiotics to the airways while simultaneously reducing the 
potential side effects inherent to the systemic absorption occurring with oral or 
intravenous (IV) delivery (Brodt, Stovold and Zhang, 2014).  
Most widely used inhaled antibiotics generally focus on treating chronic infection 
with P. aeruginosa by colomycin, tobramycin and gentamicin (Chalmers et al., 
2015). It is worth noting that these antibiotics have also been reported to elicit 
significant problems of tolerability among patients and further trials are needed to 
determine whether the benefits outweigh the potential complications involved with 
their use in patients with bronchiectasis. 
To sum up, all these treatments always come at a risk of promoting antibiotic 
resistance and side effects and therefore, it is important to stress the need for 
therapy to be tailored to each patient and only intensified when necessary and make 
sure the side effects do not outweigh the intended benefits of the therapy. In 
addition, in the long term, limiting of antibiotic prescriptions will also result in a 
reduction of the healthcare spending (Chalmers et al., 2012).        
1.1.4. Propensity for infections  
As mentioned previously, patients with bronchiectasis are prone to infections: more 
than two thirds of patients with bronchiectasis are chronically colonised with bacteria 
(Hill, 2012). An interesting hypothesis is that, due to the “vicious cycle of 
inflammation and infection”, resulting antibiotic therapy disrupts the lung microbiome 
leading to a simplified microbiota with some empty niches that leave room for further 
establishment of microbial pathogens (Boyton, 2012). Some of the most common 
colonising organisms in bronchiectasis are Haemophilus influenzae, Streptococcus 
pneumoniae and Pseudomonas aeruginosa (King, 2011). These are opportunistic 
pathogens and all share the selective ability to adhere to the epithelium in the airway 
and produce biofilms that protect them from immune components stimulated by their 
presence (King, 2011). Another less common bacterial infection also reported in 




1.2. Stenotrophomonas maltophilia 
S. maltophilia is not found in the human natural flora but it is commonly found as an 
opportunistic pathogen in immunocompromised patients (Denton and Kerr, 1998). 
One of the first reported cases of S. maltophilia in bronchiectasis was from a study 
case from 1993 where the mucoid version of the opportunistic pathogen was found 
to be the cause of a pneumonia in a bronchiectasis patient (Irifune et al., 1994). 
Unlike the more common pathogens previously mentioned, nothing has yet been 
published about the role of S. maltophilia in bronchiectasis and little is known about 
its effects on the disorder nor the causes for infection.  
1.2.1. Classification 
S. maltophilia was first attributed its own genus in 1993 (Palleroni and Bradbury, 
1993) after being characterised initially as a member of the Pseudomonas genus by 
Hugh and Ryschenkow (1961) and later controversially moved to the genus 
Xanthomonas mainly based on segmental DNA homology by Swings et al. (1983). 
S. maltophilia is an aerobic non-fermenting and generally oxidase negative, Gram-
negative bacillus from the gamma proteobacteria class (Crossman et al., 2008).  
The genus Stenotrophomonas is currently composed of eight different species (S. 
maltophilia, S. nitrireducens, S. acidaminiphila, S. rhizophila, S. koreensis, S. 
chelatiphaga, S. terrae and S. humi) which have been determined following 
phenotypic and genotypic analysis. All species are widely found in the environment 
where they seem to hold a leading role in nitrogen and sulphur cycles from which 
many plants benefit (Ryan et al., 2009).  
The particularity of the S. maltophilia species is that it is the only species from the 
genus known to be pathogenic to humans (Ryan et al., 2009). It was initially only 
considered as a commensal but there is increasing evidence to show that it can also 
be a true pathogen. Its infection can originate in a variety of tissues and lead to 
serious complications, bacteraemia being the most common. It is usually caused by 
contaminated intravascular devices, ultimately leading to septicaemia with a high 
mortality rate (Denton and Kerr, 1998). It is worth noting that the respiratory tract 
remains the principal site of isolation of S. maltophilia from patients and accounts for 
the origin of 56 to 69% of total isolates. Lungs usually become infected through the 
use of contaminated nebulizers which can subsequently cause pneumonia (Denton 
and Kerr, 1998). 
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1.2.2. Intrinsic multidrug resistance 
S. maltophilia is characterised by intrinsic drug resistance to a broad array of 
antibiotics such as macrolides, β-lactams, aminoglycosides and quinolones (Brooke, 
2012). Evidence suggests this multidrug resistance is mainly conferred by efflux 
pumps; a comparative genomic analysis of strains from both environmental and 
clinical origin for which full genome sequences are available identified around 50 
genes involved in multidrug resistance in each of the strains, of which about 40 to 
50% are operons for efflux pumps (Youenou et al., 2015).  
From, the same study, it was observed that environmental strains often carried a 
superior amount of efflux pumps than the clinical strains. This supports the fact that 
these pumps most likely play additional roles related to the natural habitat of S. 
maltophilia such as detoxification of heavy metals and solvents, trafficking of 
quorum-sensing molecules, providing it with valuable assets to compete against 
other bacteria sharing its ecological niche (Youenou et al., 2015).  
Thus, it seems that no antibiotic or anthropic selective pressures were required for 
S. maltophilia to develop its intrinsic antimicrobial resistance but it is rather an 
outcome of the natural selection for its beneficial properties in its natural habitat 
(Martínez, 2008). Furthermore, Youenou et al. (2015) also revealed in their study a 
high functional redundancy in the genes coding for efflux pumps since the lack of 
one did not necessarily correspond to a loss of its function.  
1.2.3. Genomic variation 
Comparative analysis of the available sequences allowed to define the core genome 
of S. maltophilia as being composed of 1,647 conserved proteins, the remaining 55 
to 65% of proteins forming the accessory genome (Youenou et al., 2015). This 
provided further evidence that a significant part of S. maltophilia antimicrobial 
resistance is not clonal but acquired, probably through horizontal gene transfer. This 
illustrates the tremendous level of genomic variation in S. maltophilia.      
1.2.4. Biofilm formation 
S. maltophilia is quite ubiquitous in the environment as a waterborne bacteria and 
has been isolated from roots, soil, wastewater plants and salad (Qureshi et al., 
2005). As a pathogen, another feature that confers it a selective advantage to easily 
grow in hospital settings is its high production of appendages such as fimbriae and 
pili. These explain the remarkable ability of S. maltophilia to form biofilms and allow 
it to adhere to plastic surfaces on indwelling devices from which it can easily reach 
an immunocompromised host organism in which to settle (Denton et al., 2003). In 
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such cases, infection can generally be treated by removal or replacement of the 
contaminated device.  
1.2.5. Virulence 
S. maltophilia is not very virulent, there is no evidence of patient-to-patient 
contamination and, even within wards, patients infected carry different –and often 
multiple– strains (Brooke, 2012). In fact, many studies have shown that clinical 
strains of S. maltophilia have a higher frequency of mutation than strains isolated 
from the environment; they can easily adapt to the local environment of their host 
(Berg, Roskot and Smalla, 1999). The only instances of community outbreaks 
reported have been as a result of infection from direct contact with ICU healthcare 
workers carrying the bacteria on their hands (Schable et al., 1991).  
With their great capacity to adhere to surfaces by forming biofilms (Guyot, Turton 
and Garner, 2013), an easy step to prevent contamination of immunocompromised 
people is to carefully disinfect drinkable water distribution systems using 3% 
hydrogen peroxide which was proved to be efficient against S. maltophilia 
(Sacchetti, De Luca and Zanetti, 2009). However, such route of transmission is not 
likely to be a significant threat of contamination since studies have been unable to 
show a correlation between strains of S. maltophilia present in the water from 
hospital environments with the pathogenic strains isolated from patients (Marzuillo et 
al., 2009).  The most common cause being infection from contaminated 
intravascular devices or following surgery (Miles, Denton and Kerr, 1998), the best 
precaution remains to avoid unnecessary interventions and ensure the sterility of all 
the tools used during these procedures. 
1.2.6. S. maltophilia in the environment 
In the environment, S. maltophilia is widely found in the rhizosphere, plants and soil 
although not as a phytopathogen but rather in beneficial associations eliciting 
favourable effects on its hosts such as favouring growth and health of plants (Ryan 
et al., 2009). Its unique ability to survive under nutrient-limited conditions and its 
biochemical properties reveal it as a promising biotechnological tool for 
bioremediation and phytoremediation (Binks, Nicklin and Bruce, 1995; Mukherjee 
and Roy, 2016).  
However, further studies are needed to assess the potential risk of spreading 
resistance genes from environmental sources to human pathogens since evidence 
suggests that environmental isolates carry an even greater amount of resistance 
genes than clinical isolates (Brooke, 2012). Hence, such application would require 
very controlled settings and careful monitoring. 
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1.2.7. S. maltophilia as a human pathogen 
On the other hand, the clinical isolates of S. maltophilia are characterised by a 
higher rate of mutation and a great ability for adaptation to their host microbial 
environment. In fact, in their genomic functional analysis Crossman et al. (2008) 
identified a subgroup referred to as ‘phylogenic group A’ of S. maltophilia that were 
very similar despite their unrelated sites of isolation and seemed to have a greater 
capacity to cause infection than other S. maltophilia strains (Crossman et al., 2008). 
They shared resistance-nodulation-division (RND)-type efflux pumps genes 
conferring them additional antimicrobial resistance to a variety of drugs. Hence, the 
biggest fear is that, despite not being a very virulent organism, S. maltophilia could 
act as a reservoir of resistance for more commonly found pathogens such as 
Pseudomonas aeruginosa, Serratia marcescens and other pathogens that can be 
co-cultured with it (Crossman et al., 2008). 
1.2.8. Treatment of S. maltophilia infection 
Treatment of S. maltophilia is particularly difficult due to its wide multidrug 
resistance; the current optimal treatment for S. maltophilia infection is 
trimethoprim/sulphamethoxazole (TMP-SMX) regime (Senol, 2004). However, with 
the spread use of antibiotics that favours selection of mutations leading to improved 
resistance, TMP-SMX resistant strains are becoming increasingly common (Brooke, 
2012). A study suggests the acquisition of such resistance from plasmids and 
transposons containing sul genes (Toleman et al., 2007). To overcome such 
resistance, combinational antibiotic regimes such as ticarcillin-clavulanic acid (TC-
CL), a beta-lactam and TMP-SMX can be prescribed to treat highly resistant strains 
(Milne and Gould, 2012).  
Other antibiotics prescribed to patients with allergies or resistant to the previously 
mentioned ones include tetracyclines such as minocycline, levofloxacin and 
doxycycline (Flamm et al., 2016). However, it is important to highlight the lack of 
evidence of effectiveness of such antibiotic treatments in vivo and the need for 
controlled and disease-specific trials (Amin and Waters, 2014). 
1.2.9. S. maltophilia in cystic fibrosis 
S. maltophilia has been extensively studied in cystic fibrosis (CF) patients since it 
represents one of the major potential pathogens, being found in up to 30% of 
patients presenting bacterial infections (Denton et al., 2000).  
CF is an autosomal recessive genetic disease affecting multiple organs and is 
caused by a mutation on chromosome 7. The most common one consists of the 
deletion of a single amino acid, F508 (O’Sullivan and Freedman, 2009). Any 
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mutation on chromosome 7 results in the disruption of the cystic fibrosis 
transmembrane regulator (CFTR) protein which is a chloride channel found quite 
ubiquitously in the body on the membrane of epithelial cells and, importantly, plays a 
key role in the regulation and transport of salt and water (Bilton, 2008). Due to its 
ubiquitous location, malfunction of the CFTR leads to a plethora of disorders in 
every organ with a secretory function. In the pancreas, it can lead to malabsorption; 
some patients also exhibit biliary duct plugging and in the reproductive system, it 
can cause infertility. However, the main cause of death among CF patients is 
respiratory failure due to the lung damage produced by impairment of the 
mucociliary clearance apparatus and subsequent mucus plugging (Bilton, 2008). 
These lead to recurrent infections with Staphylococcus aureus, P. aeruginosa, 
Haemophilus influenzae, Burkholderia cepacia complex, S. maltophilia and 
Achromobacter xylosoxidans. Cystic fibrosis represents the most common inherited 
disease among the Caucasian population since about 1 in 25 Caucasians are 
believed to be carriers (Denton et al., 2000). Treatment and management of the 
disease such as physiotherapy, DNase, antimicrobial therapy and hypertonic saline 
treatment have considerably extended the life expectancy of CF patients in the last 
decades, with most of them reaching adulthood and being able to carry a relatively 
normal life, attending education and contributing to the workforce (Bilton, 2008).     
Effects on cystic fibrosis 
Despite the high incidence of S. maltophilia in CF the question of whether it is a true 
pathogen contributing to deterioration of the lung function in patients is still 
controversial (Colin and Rabin, 2011). An initial study on the serological response in 
chronically infected CF patients showed increased antibody levels to S. maltophilia 
compared to patients only presenting acute infection (Waters et al., 2011). It was 
thus proposed that chronic infection due to S. maltophilia could be considered a risk 
factor for exacerbation. Nevertheless, these findings are not enough to infer its role 
in deterioration of the lung function; further studies are needed to determine this 
causality by looking at the chronicity of the events (Colin and Rabin, 2011). In fact, 
the opposite could also be true; the presence of S. maltophilia could be a 
consequence of the progression of the disease without itself being responsible for 
the deterioration of lung function. In such cases, the bacterial infection would be 
more of a “secondary effect” to the progression of the disease rather than its driver. 
In addition, the subsequent evidence of rising titres of antibodies against S. 
maltophilia would thus be solely due to the presence of the bacteria in an already 
damaged lung (Colin and Rabin, 2011).  
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1.2.10. S. maltophilia in bronchiectasis 
So far, S. maltophilia has not been studied in bronchiectasis as it is not as common 
as in CF (Boyton, 2012). Nevertheless, both diseases share the phenotype of 
accumulation of sputum in the lungs, which is a favourable reservoir for growth of 
bacteria and a main contributor to the high incidence of bacterial infections in 
patients affected by such diseases. Therefore, it is important to establish the 
differences and similarities of both diseases and of the impact of S. maltophilia 
infection in both. A lot can be learnt from previous studies in CF and similarly from 
the gaps in the understanding of S. maltophilia in CF such as the paradigm for the 





The aims of this project were to: 
1. Investigate the prevalence of S. maltophilia in bronchiectasis and its clinical 
impact; 
2. Compare strains isolated from patients with bronchiectasis and patients with 
cystic fibrosis as well as environmental strains isolated from salad samples 
and determine whether the clinical strains and environmental ones differ; 




3. Materials and Methods 
3.1. Data collection 
All the data from databases were extracted from TrakCare®, the NHS database: 
pulmonary function, BMI and other variables required for the calculation of patients’ 
BSI were found in clinic notes and the serological parameters under the blood 
results section, the sputum bacteriology results from the clinical labs, under the 
microbiology section. 
3.2. Isolation of S. maltophilia strains 
Clinical S. maltophilia strains from bronchiectasis patients were isolated from 
sputum. When isolated from fresh sputum the following routine procedure was used: 
the sputum was weighed and an equal volume of Sputolysin (Calbiochem, Millipore 
(UK) Ltd., Watford) was added; then 1 in 10 dilutions in sterile saline were made and 
10-2 and 10-4 dilutions were plated onto PIA –Pseudomonas Isolation Agar (Difco), 
BA –Blood Agar (Columbia agar base plus 5% horse blood –Oxoid) and CBA –
Chocolate Blood Agar (Columbia agar base plus 5% horse blood, heated plus 
bacitracin, 0.35mg/ml). They were incubated at 37°C for 48h and colonies were 
subsequently counted (annexe 1).  
Suspected S. maltophilia strains from PIA plates were then sub-cultured onto 
Nutrient Agar (NA) and MacConkey Agar plates for 24h at 37°C. In most cases, 
MacConkey agars should turn orange and colonies from the NA were picked to 
perform API® 20NE tests (BioMérieux), following the manufacturer’s protocol. The 
results from the API® 20NE were recorded after both 24h and 48h incubation at 
30°C and identity was subsequently confirmed entering the results in the apiweb™ 
online tool. Strains were stored in triplicate by taking out three single colonies into 
three different cryotubes containing 1ml of 10% skimmed milk (Oxoid) and stored at 
-70°C. 
Some of the clinical samples were thawed from frozen neat sputum from previous 
studies stored at -70°C. Those were streaked straight onto PIA and BA using a loop. 
They were then incubated for 48h at 37°C and sub-cultured on NA and MacConkey 
agar. Subsequently, API® 20NE was performed as previously mentioned.  
Isolation of environmental isolates of S. maltophilia from salad packs were 
homogenized with saline and plated onto selective VIA (Vancomycin Imipenem and 
Amphotericin B) medium for S. maltophilia –in addition to the PIA, BA and CBA 
plates. VIA was prepared following Denton’s paper (Denton et al., 2000) using 1mg 
of vancomycin (900g/mg), 1mg of amphotericin B (80%) and 7mg of imipenem into 
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200ml of distilled water mixed with mannitol solution (Mast Diagnostics Ltd.)100l of 
the saline solution was spread onto the VIA plates and incubated at 37°C for 48h.  
3.3. Antimicrobial Susceptibility Testing (AST) 
3.3.1. Disk diffusion method 
Strains were plated onto NA and incubated at 37°C for 24h and colonies were 
subsequently grown in nutrient broth (NB) enriched with 0.5% Yeast Extract (YE) 
(Oxoid) and incubated overnight at 37°C in an orbital incubator (Sanyo). 10 µl of the 
broth was diluted 1:100 in 0.85 % saline and used to flood seed DST agar plates. 
Excess solution was removed and discarded and the specific antibiotic discs were 
distributed on the agar plates which were then incubated overnight at 37°C. After 
incubation, sensitivity was recorded by measuring the diameter of the zone of 
inhibition around the disks and compared to the standard values given for each 
antibiotic disk by the manufacturer.  
3.3.2. Etest method 
S. maltophilia colonies grown on nutrient agar at 37°C for 24h were diluted into 10 
ml of saline and cell density was adjusted by measuring the turbidity of the samples 
against a McFarland Standard 0.5 from Pro-Lab Diagnostics in a Nephelometer 
Sensititre® from Thermo Scientific. Diagnostic sensitivity testing (DST) agar plates 
were flood seeded with the bacterial suspension and excess solution was removed. 
Etest® strips from BioMérieux of the corresponding antibiotic were then placed at 
the centre of the plate using sterilised forceps. The plates were incubated at 37°C 
overnight and the minimum inhibitory concentration (MIC) was then recorded as the 
concentration which demonstrated inhibition of growth on the strip (annexe 2).  
3.4. Pulsed-Field Gel Electrophoresis  
3.4.1. Plug Preparation 
Fresh S. maltophilia bacterial cells grown for 24h at 37°C on non-selective NA plates 
were suspended in 1ml SE buffer, in Eppendorf tubes and centrifuged for 2 mins at 
13 000 rpm. The pellets were re-suspended in 500 l of SE buffer but the volume 
was adjusted depending on the size of the pellet to give an uniform cell density for 
each isolate. The bacterial cells were encased in an agarose matrix made up of 
1.5% low melt agarose (Bio-Rad Laboratories) in SE buffer (0.15g of low melt 
agarose in 10ml of SE buffer), previously microwaved for 15 secs and then 4 times 5 
secs, gently mixing between every heating. An equal volume of 1.5% low melt 
agarose solution was added to the bacterial suspension in SE buffer and 
subsequently pipetted into the plug mold. Plugs were left at 4°C for 15 mins to 
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solidify. Plugs were then transferred into small bijoux containing 2 ml of lysis buffer 
and 10 l Triton X-100 (Sigma) and incubated overnight in a waterbath at 55°C. 
Plugs were then washed by removing the lysis buffer and replacing it with 2 ml of TE 
buffer for 30 mins at 4°C and repeating this step carefully another two times to 
ensure removal of any potential cellular debris that would prevent proper digestion in 
later steps. 
3.4.2. Restriction Enzyme Digestion 
A small portion of each plug of approximately 2 mm was cut and placed in an 
Eppendorf tube filled with 90 l of distilled water (DW) and 10 l of reaction buffer 
(10X REact® 2 buffer; Invitrogen™) and placed in a fridge at 4°C for 30 mins. The 
buffer was carefully removed using a fine Pasteur pipette and replaced by a solution 
containing 90 l of DW, 10 l of reaction buffer, 2 l of bovine serum albumin (BSA 
1 mg/ml; New England BioLabs® Inc.), 2 l of dithiothreitol (DTT 1.5 mg/100 l DW) 
and 2 l of restriction enzyme (XbaI; Invitrogen™) in which the plugs were incubated 
overnight at 37°C in a waterbath.  
3.4.3. Loading of Plug Slices and Running of the Gel 
2L of 0.5% TBE buffer (Severn Biotech Ltd.) was made and 150 ml of it was used 
for making the gel, to which 1.5 g of pulsed-field agarose (Bio-Rad Laboratories) 
was added and the mix was microwaved for 1 min, then mixed and again 
microwaved for 1 min 10 sec. Once cooled, the agarose was poured into the gel 
mold previously cleaned with ethanol, and allowed to solidify for 30 mins. Finally, the 
plugs were placed in the wells and the gel was placed in the CHEF-DRII gel tank 
(Bio-Rad Laboratories) and the remainder of the 2L of TBE buffer was added. The 
chiller was set at 14°C and parameters were set as follows: initial time 2.9 secs, final 
time 35.4 secs, voltage 6 volts/cm, run time 20h.  
3.4.4. Image Analysis 
The gel was stained with gel red (7.5µl in 250ml of 0.1M NaCl) for visualization 
under UV trans-illumination using the Molecular Imager® GelDoc™ XR+ system 
with Image Lab™ software (Bio-Rad Laboratories). The exposure time and 
saturation were adjusted to obtain optimal pictures with distinct bands. 
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3.5. Virulence factors 
3.5.1. Lipase 
Specific agar for this test was composed of 85ml nutrient agar and 15ml of egg-yolk 
emulsion (Oxoid). The NA was autoclaved and the egg-yolk emulsion added after 
cooling to room temperature. A few colonies of each test isolate, taken from a NA 
plate, were inoculated into 10ml of NB containing 0.5% YE and incubated overnight 
at 37°C in an orbital incubator. The plates were then inoculated with the different 
isolates of S. maltophilia using a multiporin inoculator and incubated overnight at 
37°C. Zones of opalescence indicated the production of lecithinase and an 
iridescent layer indicated lipolysis, which are markers of virulence. The positive 
control was an isolate of P. aeruginosa (ATCC).  
3.5.2. Protease 
Specific agar for this test was 100ml of brain heart infusion (BHI) broth (Oxoid) + 3% 
Bacteriological agar (Oxoid) and equal volume of 3% skimmed milk (100ml) (Oxoid). 
Each component was autoclaved separately and then mixed and poured into petri 
dishes. The same broth (NB+0.5% YE) culture for each test isolate, as used for the 
Lipase experiment was used to inoculate the Protease plastes, using the multiporin 
inoculator and the plates were incubated at 37°C overnight. A clear zone around the 
bacterial growth indicated protease activity, which is a marker for virulence.  
3.5.3. Elastase 
Specific agar used to test elastase activity of the isolates was made of 100ml of 
autoclaved NA to which 0.3% of elastin Congo red (Sigma) was added before 
pouring the plates. The plates were then inoculated as described above overnight at 
37°C. 
3.6. Inflammatory markers in sputum 
3.6.1. Preparation of spun sputum supernatant for MPO and NE assays 
Sputum was collected in a sterile container and processed within 4h. Approximately 
1ml was required for routine qualitative microbiology by the hospital laboratories. If 
there was enough left over, another 1ml was used for further quantitative and 
qualitative microbiology by the research laboratory and the remaining –if any– was 
then spun down at 23 200 rpm for 1h30mins at 4°C in the ultracentrifuge (Discovery 
S-100, Sorvall). The supernatant was then collected and frozen directly at -70°C for 




3.6.2. Myeloperoxidase (MPO) assay 
MPO activity was measured by a chromogenic substrate assay. All reagents were 
preliminarily brought to room temperature. Myeloperoxidase from Calbiochem® and 
spun sputum samples were diluted as required in phosphate buffer solution by 
adding 1.5 l of sample into 73.5 l of buffer. 25l of standards or samples solution 
were added to the wells of a flat-bottomed 96 well microtitre plate (Costar®), each in 
duplicate. After that, 25 l of tetramethylbenzidine (Sigma-Aldrich®) was added to 
each well and the plate was left at room temperature for 5 mins. The reaction was 
then halted by the addition of 50 l of sulphuric acid (H2SO4) to each well and the 
absorbance was recorded at a dual wavelength of 450 and 50 nm and the MPO 
concentration was extrapolated from the standard curve and expressed as g/ml. 
Since samples were all performed in duplicate, the mean of both values was 
calculated.   
3.6.3. Free Elastase Activity (Neutrophil Elastase, NE) assay 
Free elastase activity was measured by spectrophotometry using the synthetic 
substrate N-Methoxysuccinyl-Ala-Ala-Pro-Val p-Nitroanilide (Sigma-Aldrich®). 
Standards (NE from Sigma-Aldrich®) and spun sputum samples (2 l) were diluted 
as required in buffer (98 l). 40 l of the standard or sample solutions were added to 
each well of a flat-bottomed 96 well microtitre plate (Costar®). 200 l of 
MeOSAAVpNa was added to 4.8 ml of buffer. 40 l of this solution was added to 
each well and samples read immediately at 37°C for a minimum of 30 mins with 
readings every 2 mins; at an optical density (OD) of 405 nm. The rate of change in 
optical density was converted into elastase activity and expressed in g/ml. The 
elastase concentration for each sample was determined in duplicate and the mean 
was calculated for each. 
3.7. Data analysis 
All the data were tested for normality using the Shapiro-Wilk test and according to 
the data distribution, either Kruskal-Wallis or Mann-Whitney U-test was used to 
compare groups. Chi squared (²) was used to compare groups for categorical data. 
Data are presented as n (%), mean (standard deviation) or median [interquartile 
range], unless otherwise stated. Differences were considered significant when p-
values were lower than 0.05. Analyses and graphs were made using the following 
softwares: SPSS Version 19 for Windows (IBM Corp., Armonk, NY, USA) and 
GraphPad Prism 5.01 for Windows (GraphPad Software, La Jolla, CA, USA), as well 




4.1. Prevalence of S. maltophilia in bronchiectasis 
To have an idea of the importance of S. maltophilia in our cohort of bronchiectasis 
patients, a retrospective analysis of the database was performed by looking at the 
microbiology of all the bronchiectasis patients in a 3-years’ timeframe (2013-2016) 
using TrakCare®, the NHS database. Out of 458 patient found in clinic notes from 
the last 3 years, a total of 37 patients (~8%) grew S. maltophilia at some point.  
The first observation is that most of the patients growing S. maltophilia in their 
sputum belong to the higher spectra of bronchiectasis severity. Most of them have 
severe bronchiectasis and the rest are moderate, with a single patient described as 
having mild bronchiectasis (Fig. 4.1).  
 
 
Figure 4.1 Severity of bronchiectasis among the patients who grew S. maltophilia from 2013 
to 2016. The majority were severe (62%) and moderate (35%) whereas only one (3%) had 
mild bronchiectasis. 
 
All the episodes of S. maltophilia in these 37 patients’ sputum reported in their 
microbiology notes were collected using TrakCare® and accounted for a total of 
242. In the majority of these cases (186 episodes, 76.9%), S. maltophilia was 
isolated on its own, as a monoculture whereas in the remaining 85 episodes, it was 
found along with other pathogen(s). The most common co-cultured organisms were 




Figure 4.2 Frequency and identity of co-pathogens isolated along with S. maltophilia. a) In 
76,9% of the cases, S. maltophilia was isolated on its own. b) When it was with other 
organism(s) the most common ones were P. aeruginosa (20,6%), S. aureus (19,0%) and 
fungi (12,7%). 
Out of the 37 patients from which S. maltophilia was ever reported in the sputum, 20 
had a single isolation only and the remaining 17 presented two or more episodes 
within a year, at least three months apart –hence, considered as chronically 
infected. Interestingly, there was no significant difference (p-value = 0.62) in the BSI 
score between the two groups (i.e. chronically infected and single isolation) (Fig. 
4.3).  
 
Figure 4.3 Comparison of BSI score of patients from which S. maltophilia was isolated 
chronically or intermittently in sputum samples. No significant difference of BSI was found 
between the two groups (p-value = 0.62). 
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The initial plan was to compare white cell counts, ESR and CRP between single 
versus chronically infected groups but this was abandoned as there was a lot of 
missing data.  
Instead, another more exhaustive database solely containing data from episodes of 
bronchiectasis patients during IV antibiotic treatment was studied. Interestingly, S. 
maltophilia had a proportionally higher incidence but not reaching conventional 
statistical significance (~13%, p = 0.13) when compared to its incidence among 
entire bronchiectasis cohort (Fig. 4.4).  
 
Figure 4.4 Comparison the incidence of S. maltophilia among the entire bronchiectasis 
cohort and the cohort of bronchiectasis patients on IV antibiotics. 
This database was divided into three groups: (1) 11 episodes of S. maltophilia 
isolations at baseline (before IV treatment) with complete data available were 
identified and they were then matched in a 1:2:2 with episodes of (2) P. aeruginosa 
and (3) H. influenzae from patients of same gender and similar age and BSI –when 
possible (annexe 3). Such ratio was chosen due the low incidence of S. maltophilia 
episodes encountered and they were compared to P. aeruginosa and H. influenzae 
since these are the most common pathogens in bronchiectasis (Dimakou et al., 
2016). 
General variables about the lung function such as FEV1 % predicted and FVC % 
predicted were compared as well as serological markers including white cells counts 
(WCC), platelets levels, ESR and CRP. 
As shown below in Table 4.1, there was no statistically significant difference in 
spirometry, white cell count, ESR or CRP between groups at the start of an 





Table 4.1 Lung function and serological variables for each group of episodes (S. 









Lung function:     
 FEV1 % predicted 36.3 [30.7 – 59.0] 51.9 [41.6 – 60.5] 52.0 [30.7 – 78.0] 0.25 
 FVC %  predicted 65.3 [54.3 – 83.8] 72.7 [67.2 – 79.8] 70.0 [52.8 – 105.6] 0.45 
WCC [4.0-11.0 x 109/l]  6.8 [5.9 – 9.4] 9.3 [3.6 – 12.9] 8.0 [6.7 – 9.8] 0.05 
Platelets [150-400 x109/l] 271 [245 – 331] 326 [272 – 436] 308 [217 – 406] 0.45 
ESR [3-15 mm/hr] 28 [16 – 77] 27.5 [19 – 39.0] 15.5 [5.7 – 32.7] 0.06 
CRP [0-5 mg/l] 12.0 [4.4 – 31.0] 13.0 [9.0 – 33.7] 9.0 [4.0 – 34.2] 0.44 
 
However, it is worth noting that the p-value is close to being significant for two of the 
variables: white cell counts (WCC) and ESR. When looking more closely at the data, 
the WCC ranges among normal values despite the different medians in each group.  
On the other hand, regarding ESR, the S. maltophilia group shows a similar value to 
that of P. aeruginosa, which both fall above the normal range (3-15 mm/hr) whereas 
the median value for the H. influenzae group is a lot closer to the normal range 
(Table 4.1).  
 
Table 4.2 Variables for each group of episodes (S. mantophilia, P.aeruginosa and H. 









Improvement in Lung function:     
 FEV1 % predicted 2.1 [-1.2 – 4.6] 1.7 [0.0 – 4.8] 1.3 [-2.4 – 4.4] 0.86 
 FVC %  predicted 2.9 [-2.7 – 12.7] 5.8 [-2.9 – 7.6] 4.5 [-7.1 – 8.5] 0.94 
WCC [4.0-11.0 x 109/l]  6.6 [5.1 – 7.1] 9.8 [7.6 – 11.8] 7.6 [6.1 – 8.6] 0.003 
Platelets [150-400 x109/l] 284 [256 – 327] 298 [249 – 403] 280 [228 – 389] 0.73 
ESR [3-15 mm/hr] 19 [14.0 – 41.0] 22 [17.0 – 27.5] 9 [4.0 – 19.5] 0.006 
CRP [0-5 mg/l] 6.0 [2.0 – 25.0] 9.5 [5.0 – 14.7] 3.0 [2.0 – 10.2] 0.23 
 
Further longitudinal analysis looked at the same variables after the 14-day IV 
antibiotic treatment and found this time a significant difference (p-value < 0.05) 
between the three groups for both the WCC and ESR.  The white cell count was 
slightly higher in the P. aeruginosa group compared with the other groups although 
the median value remained within the normal range (Table 4.2).  
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More interestingly, regarding the ESR levels, antibiotic treatment appeared to bring 
the values into the normal range among the group that had tested positive for H. 
influenzae at baseline. However, the values for both the S. maltophilia and P. 
aeruginosa remained above the normal range (Table 4.2).  In fact, further statistical 
analysis revealed a statistical difference in the ESR values between the S. 
maltophilia group and the H. influenzae group (p-value = 0.013) and between the P. 
aeruginosa group and the H. influenzae group (p-value = 0.003) but not between the 
S. maltophilia and P. aeruginosa groups (p-value = 0.85).  
4.1.1. Incidence of S. maltophilia among the IV sub-group 
Following the relatively high incidence of S. maltophilia among the IV sub-group, its 
incidence in this cohort was further analysed.  
All the recorded courses of IV antibiotics between 2013 and 2016 were collected 
and accounted for 237 14-day IV antibiotic courses from 74 different patients (some 
were under long-term preventative IV treatment; others were related to treatment for 
exacerbations according to the BTS guidelines). The organisms grown at baseline 
(day 0) (Fig. 4.5 (a)) were compared to those isolated from sputum at the end of the 
14-day IV antibiotic course (Fig. 4.5 (b)).  
 
 
Figure 4.5 (a) Organisms isolated at baseline prior to 237 episodes of 14-day IV course 




Figure 4.5 (b) Organisms isolated at the end of the 237 episodes of 14-day IV course. 
The main observation regarding S. maltophilia is that its incidence increases after 
the IV antibiotic course as opposed to P. aeruginosa for which occurrence is almost 
halved by the IV antibiotic course (Fig. 4.5 (a) & (b)). However, these results could 
be disproportionally influenced by single individuals on regular IVs that account for a 
significant proportion of incidence of a particular bacterium. Therefore, to confirm the 
previous observations, the organisms were also compared per patient rather than IV 
antibiotic course, looking at the organisms isolated at baseline and end of 14-day IV 
antibiotic course of the earliest IV antibiotic course recorded since 2013 (Fig. 4.6 (a) 
& (b)).  
 
Figure 4.6 (a) Organisms isolated at baseline prior to the first IV-course starting from 2013 




Figure 4.6 (b) Organisms isolated at the end of the first IV-course starting from 2013 
recorded for each of the 74 patients from the IV database. 
 
Interestingly, a similar trend was observed, consistent with the previous comparison 
of organisms per episodes (Fig. 4.5 (a) & (b)): H. influenzae, S.aureus and P. 
aeruginosa were all relatively successfully eliminated following the 14-day IV 
antibiotic course whereas S. maltophilia appeared at a higher incidence after the IV-
course (Fig. 4.6 (a) & (b)).   
To check whether IV treatment had triggered the appearance of S. maltophilia 
among the 10 patients from the IV database that were found to isolate it in their 
sputum, their full microbiology was examined on TrakCare®. All recorded episodes 
of S. maltophilia were summarised and their chronology with respect to the start of 
IV therapy was analysed (Fig. 4.7). 
For most of them (80%), IV-treatment appeared to trigger an increase in incidence 
of S. maltophilia: for four patients, IV treatment appeared to switch the frequency of 
isolation of S. maltophilia from intermittent to chronic, for three patients, it went from 
non-existent to chronic and in one patient S. maltophilia was isolated intermittently 




Figure 4.7 History of the frequency of isolation of S. maltophilia among the 10 patients with 
S. maltophilia from the IV sub-group. 
 
To see whether this was due to a particular antibiotic that favoured S. maltophilia, a 
closer look was given to the specific antibiotic given to each of the 10 patients 
(Figure 4.8). 
 
Figure 4.8 Type of IV antibiotic given to the 10 S. maltophilia patients from the IV subgroup. 
As shown in Figure 4.8, the 10 patients were given a variety of antibiotics and thus 
the subsequent isolation of S. maltophilia in their sputum could not be attributed to a 
particular antibiotic but perhaps to IV-treatment in general. 
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4.1.2. Incidence of S. maltophilia following nebulised versus IV antibiotic 
treatment 
Following the interesting observations made on the IV sub-group, another 
retrospective data analysis was performed looking at the microbiology of patients 
currently on long-term IV (every 2-3 months) and another set of patients currently on 
long-term nebulised antibiotics –it is worth noting that there was some overlap 
between the two sub-groups with some patients receiving both long term IV and 
nebulised antibiotic treatment, these were counted as part of the IV sub-group. The 
list of current patients in each category comprised 16 individuals. Again, their 
microbiology was examined using TrakCare® and noting any episode of S. 
maltophilia prior or post to long-term antibiotic therapy. Then, a longitudinal 
comparison between their most common colonising organism prior to the long-term 
antibiotic treatment and 1-year follow-up was performed (Fig. 4.9 (a), (b), (c) & (d)).  
 
 

















Figure 4.9 (d) Dominant organisms isolated 1 year after long-term IV antibiotic therapy. 
 
Remarkably, the patterns were very different between the two groups: long-term 
nebulised antibiotic treatment did not seem to have any increasing effect on the 
incidence of S. maltophilia (Fig. 4.9 (a), (b), (c) & (d)). The history of the one patient 
where S. maltophilia persisted throughout the treatment was carefully examined and 
it was observed that they had become chronically colonised by S. maltophilia in July 
2013 following a course of IV-meropenem in April 2013, prior to the start of their 
long-term nebulised antibiotic therapy started in November 2013.  
On the other hand, a similar trend to the ones previously reported among IV patients 
was observed again among the smaller 16 patients’ cohort currently undergoing 
preventative long-term IV antibiotic therapy, four of which are also on regular 
nebulised antibiotics. S. maltophilia seemed to be favoured (p-value < 0.001) by the 
IV regime and showed a higher incidence following one year of IV therapy compared 
to its incidence at baseline of treatment. (Fig. 4.9 (c) & (d)). 
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4.2. Comparison of bronchiectasis, CF and environmental strains 
4.2.1. Gathering of the strains 
The first 6 months of the project included active tracking of patients attending clinics 
and processing of their sputum in search for fresh S. maltophilia specimens (using 
the isolation methods described in the materials and methods section with graphic 
illustrations of the characteristic appearance of S. maltophilia available in the 
annexe 1). However, the search revealed to be quite slow and unfruitful due to the 
low incidence of the bacteria and another approach was thus added: records were 
examined for potential S. maltophilia stored in frozen sputum samples from previous 
studies. These were thawed and processed like the fresh specimens.  
Eventually, a library of 18 strains isolated from sputum of 12 different bronchiectasis 
patients (10 from fresh sputum, 8 from recovered frozen sputum) was gathered. 
Another 4 environmental strains were isolated from environmental samples (mixed 
salad leaves and spinach). In total, 22 isolates of S. maltophilia constituted the 
library of strains used for the wet lab experiments (annexe 4). Another 10 isolates of 
S. maltophilia strains obtained from sputum of CF patients were provided by Dr. 
Catherine Doherty from the extensive library of strains accumulated over in the CF 
Strain Repository. 
4.2.2. Comparison of antimicrobial resistance  
To compare strains from clinical and environmental origin, an antimicrobial 
resistance experiment was designed based on the suggestions from the literature 
that environmental strains usually show a greater resistance pattern than clinical 
strains (Youenou et al., 2015).  
First, the disc diffusion method was used to identify the antibiotics worth 
investigating. Strains were tested against imipenem (IMI10), meropenem (MEM10), 
tobramycin (TN10), doxycycline (DO30) and trimethoprim/sulfamethoxazole (TMP-
SXT) (TS25).  
Due to the lack of guidelines regarding antimicrobial testing susceptibility (AST) 
breakpoints for S. maltophilia from both the Clinical and Laboratory Standards 
Institute (CLSI) (Nicodemo et al., 2004) and the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST), the only antimicrobial agent for 
which zone diameter breakpoints specific to S. maltophilia were available was TMP-
SXT (TS25) (http://www.eucast.org. 2016); for imipenem, meropenem and 
tobramycin, values from P. aeruginosa were used, considering the initial 
classification of S. maltophilia as a Pseudomonas species.  
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Unfortunately, for doxycycline, no value was available for either bacterial species or 
any other related one so it was not possible to accurately predict resistance or 
susceptibility but diameter breakpoints were still recorded and can be found in table 
4.3.   
In addition to the disc diffusion method, antimicrobial susceptibility of bronchiectasis 
and environmental strains was also tested using the Etest method. Strips for the 
same antibiotics as for the disc diffusion method were used: imipenem (IP), 
meropenem (MP), tobramycin (TM), doxycycline (DO) and trimethoprim-
sulfamethoxazole (TS) as well as minocycline (MC) –for which susceptibility results 
were frequently reported from the microbiology laboratories of the hospital for strains 
that exhibited resistance to TMP-SXT.   
On the other hand, the 10 CF strains provided by Dr. Catherine Doherty were also 
tested for antimicrobial susceptibility to imipenem, meropenem, tobramycin, 
doxycycline and trimethoprim-sulfamethoxazole using the disc method (Table 4.4) to 
compare resistance patterns to that of strains isolated from bronchiectasis patient. 
For the disc diffusion method, diameters are reported in the tables below and for the 
Etest, MIC values are reported. A colour code was used to distinguish results 
corresponding to resistance (red), intermediate resistance (orange) and sensitivity 
(green) to the respective antibiotic (Tables 4.3 and 4.4).     
There was a good correlation of the results between the Etest and disc method: as 
expected, all strains were resistant to imipenem, which is a characteristic of S. 
maltophilia. However, there was some discrepancy regarding resistance to TMP-
SXT: the disc method identified more strains as being resistant to it than the Etest 
method (Table 1). The general pattern of susceptibility revealed the highest 
sensitivity of strains isolated from patients with bronchiectasis was minocycline, 
tobramycin and TMP-SXT, respectively. 
It is worth noting that environmental strains isolated from salad samples did not 
appear to have a greater resistance pattern than the clinical strains as expected 
from literature  (Youenou et al., 2015). However, this might be due to the limited 
sample size and further studies with a higher number of samples are needed to 





Table 4.3 Antimicrobial Sensitivity Testing of S. maltophilia strains isolated from 
bronchiectasis patients and environmental samples
Strain 























Patient 1 (1) 6* 26 32 36 36 32 3 0.125 0.19 0.064 0.25 
Patient 1 (2) 6* 32 28 34 40 32 0.75 1 0.75 0.047 0.125 
Patient 2 (1) 6* 6* 6* 32 6* 32 32 256 1.5 6 0.75 
Patient 2 (2) 6* 6* 6* 28 6* 32 32 256 3 32 1 
Patient 3 (1) 6* 26 22 25 32 32 2 0.75 2 0.016 4 
Patient 3 (2) 6* 19 18 23 26 32 2 4 2 0.032 0.25 
Patient 4 (1) 6* 30 25 28 28 32 1 0.25 0.50 0064 0.25 
Patient 4 (2) 6* 25 24 31 30 32 1 1 0.75 0.64 0.094 
Patient 5 (1) 12 20 24 22 6* 16 1 0.5 3 0.25 1 
Patient 5 (2) 11 20 26 20 6* 32 2 0.75 3 2 0.25 
Patient 5 (3) 17 25 30 27 25 6 0.75 0.38 1.5 0.047 1.5 
Patient 6 6* 18 20 23 30 32 6 1.5 1 0.047 0.064 
Patient 7 6* 25 22 25 34 32 2 0.38 1 0.064 0.19 
Patient 8 6* 29 26 29 32 32 2 0.75 1 0.032 0.125 
Patient 9 6* 6* 15 32 6* 32 32 2 3 0.125 0.25 
Patient 10 6* 25 23 28 30 32 3 1 0.75 0.047 0.125 
Patient 11 6* 6* 22 38 38 32 32 1.5 0.38 0.064 0.047 
Patient 12 6* 21 6* 20 29 32 2 0.75 3 2 0.25 
Salad 1 6* 17 27 27 6* 32 0.5 2 2 0.125 1 
Salad 2 - - - - - 4 0.5 8 1 0.19 0.5 
Salad 3 6* 32 24 30 34 32 0.5 1 1.5 0.032 0.125 
Salad 4 6* 21 18 24 31 32 0.38 16 4 0.25 0.125 
*6 = diameter of the disc, organism is completely resistant in such case. 
Diameter breakpoints (mm) for each antibiotic disc (from EUCAST 2011): 
IMI10 (Imipenem): R < 18, I : 18 – 20 , S > 20**           MEM10 (Meropenem): R < 18, I : 18 – 24,  S > 24** 
TS25 (TMP-SXT): R < 16, S  16                                 TN10 (Tobramycin): R < 16, S  16**                         
MIC values (g/mm) for Etest results interpretation (from CLSI 2015):  
MC (Minocycline): R > 16, I : 16 – 4,  S < 4                    TS (TMP-SXT): R > 4, I :  4 – 2, S < 2 
IP (Imipenem): R >  8, I : 8 – 2, S < 2**                          MP (Meropenem): R > 8, I : 8 – 2, S < 2** 
TM (Tobramycin): R > 16, I : 16 – 4, S < 4** 
DO30 and DC (Doxycycline): no value was available for S. maltophilia or any related species 
** values of P. aeruginosa used                                          – Resistant (R)      – Intermediate (I)      – Sensitive (S) 
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C1932 6* 6* 6* 22 21 
C1954 6* 20 6* 21 32 
C1972 6* 14 20 17 15 
C1970 6* 6* 6* 25 20 
C1953 6* 22 19 22 20 
C1969 6* 10 6* 25 25 
C1914 6* 34 35 35 33 
C1957 6* 6* 13 27 28 
C1950 6* 6* 30 27 30 
C1936 6* 22 6* 18 25 
*6 = diameter of the disc, organism is completely resistant in such case. 
Diameter breakpoints for each antibiotic disc (from EUCAST 2011): 
IMI10 (Imipenem): R < 18, I : 18 – 20 , S > 20**      MEM10 (Meropenem): R < 18, I : 18 – 24,  S > 24** 
TS25 (TMP-SXT): R < 16, S  16                            TN10 (Tobramycin): R < 16, S  16**                        
DO30 (Doxycycline): no value was available for S. maltophilia or any related species 
** values of P. aeruginosa used                                   – Resistant (R)      – Intermediate (I)      – Sensitive (S) 
 
Additionally, there is a clear difference in resistance patterns between 
bronchiectasis and cystic fibrosis strains: isolates from cystic fibrosis patients exhibit 
a much wider resistance pattern than the bronchiectasis ones. Most strains showed 
resistance or intermediate resistance to imipenem, meropenem and tobramycin, 
making TMP-SXT the most efficient antibiotic.  
Finally, it is interesting to highlight the change in resistance pattern of some strains 
isolated from same patients (e.g. patient 5(1) and (3) and patient 3(1) and (2), disc 
diffusion method).  
To check whether this was due to a loss of resistance or simply a change of strain, 
pulsed-field gel electrophoresis was performed on the five sets of strains that 
belonged to same patients (Fig. 4.10). 
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Figure 4.10 PFGE of strains isolated from bronchiectasis patients showing fingerprinting 
Interestingly, the pulsed-field gel electrophoresis revealed that the strains from 
patient 1 and 3 had changed over time: they exhibited more than a 3-band 
difference, thus considered as being different strains whereas the others remained 
the same despite being isolated at different time points.  
The difference in strains can explain the different resistance pattern of the isolates 
from patient 3. However, the putative loss of resistance observed by disc diffusion in 
the isolates from patient 5 is not due to a change in the strain (further evidence 
supporting this is the fact that the three isolates from patient 5 had been isolated in a 
14-day period during a meropenem antibiotic course –annexe 4). A plausible 
explanation for the loss of resistance is that resistance genes come at a fitness cost 
and in scenarios where they are not essential, they could potentially be selectively 
lost (Andersson and Hughes, 2010).  
Moreover, another specificity of the set of strains from patient 3 is that it is the only 
one from sputum samples collected at different exacerbation times; all the others 
were collected in close proximity during trials prior and after antibiotic treatments, 
generally in a 14-day period at most. In contrast, the set of strains from patient 3 had 
been collected at very different time points: one was rescued from frozen sputum 
from a past study whereas the other one was collected at a clinic visit during the 
time of this project.  
   1       2     3      4      5      6      7      8      9     10 1. patient 1 (1) 
2. patient 1 (2) 
3. patient 2 (1) 
4. patient 2 (2) 
5. patient 3 (1) 
6. patient 3 (2) 
7. patient 4 (1) 
8. patient 4 (2) 
9. patient 5 (1) 
10. patient 5 (3) 
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4.2.3. Comparison of virulence factors 
For further comparison between environmental and clinical strains, some virulence 
experiments were performed that looked at lipase, elastase and protease activity, all 
common virulence markers found in bacteria (Table 4.5).  
Table 4.5 Virulence factors activity for each S. maltophilia strain 
STRAIN REF LIPASE PROTEASE ELASTASE 
PATIENT 1 (1) +++ ++ - 
PATIENT 1 (2) - +/- - 
PATIENT 2 (1) ++ + - 
PATIENT 2 (2) - +/- - 
PATIENT 3 (1) ++ +++ - 
PATIENT 3 (2) + +++ + 
PATIENT 4 (1) ++ ++ - 
PATIENT 4 (2) +++ +++ + 
PATIENT 5 (1) ++ +/- - 
PATIENT 5 (2) ++ +/- - 
PATIENT 5 (3) ++ + - 
PATIENT 6 +++ ++ - 
PATIENT 7 + +/- - 
PATIENT 8 - +/- - 
PATIENT 9 +/- +/- - 
PATIENT 10 + + - 
PATIENT 11 ++ + - 
PATIENT 12 +++ + - 
SALAD 1 ++ +++ - 
SALAD 3 +++ + - 
SALAD 4 ++ +++ - 
 
No significant difference was found between the environmental and clinical samples: 
most of them exhibited high to moderate protease and lipase activity and only two 
clinical strains had some kind of elastase activity. Only three of the four 
environmental strains could be tested as one of them (salad 2) proved unable to 
grow at 37°C. This could be due to the possession of a ‘temperature-regulated 
suicide system’ found in environmental strains that makes them unable to survive at 
body temperatures (Alavi et al., 2014). 
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4.3. Pathogenicity of S. maltophilia 
4.3.1. Myeloperoxidase (MPO) and Neutrophil Elastase (NE) activity 
Since previous studies found a relationship between P. aeruginosa infection and 
MPO and NE activity, those two inflammatory markers were chosen to test S. 
maltophilia for pathogenicity (Chalmers et al., 2012).  
Results (provided by Dr. Pallavi Bedi) from sputum samples that had grown mixed 
normal flora in patients with bronchiectasis and not chronically colonised were used 
as negative controls (n=7) since inflammatory markers in their sputum should solely 
be due to the bronchiectasis condition itself.  
Since these assays require spun sputum samples which are only stored when a 
sufficient amount is produced by the patient to cover the preliminary quantitative and 
qualitative microbiological routine, these were not systematically available for every 
S. maltophilia episode and it was quite challenging to gather a decent amount of 
them. Only 10 spun sputum samples were found. These were matched in gender 
and age with the negative controls for an accurate comparison (annexe 5). 
 
Figure 4.11 Comparison of MPO levels in sputum with MNF and in sputum with  
S. maltophilia (SM): the difference between both is not significant (p = 0.3795). 
As shown above in Figure 4.11, there was no significant difference (p-value > 0.05) 
between the levels of MPO in the sputum samples containing MNF and in the ones 
containing S. maltophilia. On the other hand, NE levels were significantly higher (*p-
value < 0.01) in sputum samples containing S. maltophilia than in the ones 




Figure 4.12 Comparison of NE levels in sputum with MNF and in sputum with  




5.1. Antibiotic treatment as a risk factor for S. maltophilia 
The results from this study support the hypothesis that S. maltophilia tends to 
appear in patients that have been exposed to strong or longer antibiotic regimes and 
thus provides evidence to suggest that aggressive antibiotic treatments could be a 
risk factor for S. maltophilia infection by promoting its establishment in 
bronchiectasis patients’ lung.  
In fact, among the general bronchiectasis cohort, most cases of S. maltophilia 
occurred in patients from the higher spectra of severity, thus having been subjected 
to more antibiotic courses due to exacerbations and progression of the disease. 
Similarly, the disparity between its incidence in CF –where patients are subjected to 
antibiotic treatment since a younger age and thus for a longer period of time– and 
bronchiectasis further supports that hypothesis.  
Nevertheless, it is important to highlight that the low rates of incidence of S. 
maltophilia in bronchiectasis might also be due to poor diagnosis and thus be under- 
or mis-reported by hospital laboratories. In fact, through this research project, a few 
occasions of discrepancies between the clinical and research laboratories was 
observed. This could be due to an uneven spread of the bacteria in the sputum 
which leads to an incomplete diagnosis as it gets split between laboratories or 
sometimes patients provide two different pots of sputum, one from the morning and 
a second one that they produce during the clinic and which could be different to 
each other. It could also be due to non-specific identification from clinical labs which 
could be solved by the use of selective media (M Denton et al., 2000), processing 
sputum quantitatively and by raising awareness for the bacterium among the staff as 
it might also get neglected and labelled as MNF, considered non-pathogenic.  
5.2. Need for sensitivity guidelines specific to S. maltophilia  
An alarming finding during this study was the lack of guidelines for antibiotic 
sensitivity specific to S. maltophilia: these were only available for TMP-SXT and 
minocycline (Hombach, Bloemberg and Böttger, 2012). The research in treatment of 
the bacterium is hugely deficient and clinicians can currently only resort to their best 
judgement when deciding whether and how to treat S. maltophilia.  
The different resistance patterns observed between CF and bronchiectasis strains 
also illustrated how current treatment is probably shaped based on studies from 
cystic fibrosis studies since the preferred treatment for S. maltophilia used in clinics 
and wards is TMP-SXT (Hand et al., 2016) 
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However, as shown in this study, despite being the most efficient antibiotic, at least 
in vitro for CF strains, other antibiotics displayed greater sensitivity among 
bronchiectasis strains, which should be further investigated in vivo, especially 
following the increasing incidence of TMP-SXT resistance in S. maltophilia (Toleman 
et al., 2007).  
5.3. S. maltophilia as a potential ‘artificial commensal’ 
An important observation highlighted by Amin and Waters (2016) in their review that 
looked at S. maltophilia in CF is the lack of guidelines for treatment of S. maltophilia 
and especially of studies that compare its treatment to its non-treatment.  
Being an intrinsically multidrug resistant organism, treatment of S. maltophilia 
implies the use of last line antibiotics (Milne and Gould, 2012) which can have 
serious side-effects and greatly affect the lung microbiome (Boyton et al., 2013). If 
S. maltophilia was proven not to be implicated in disease progression, the idea of 
avoiding its treatment at first isolation should be considered.  
Bronchiectasis patients’ normal flora most likely looks very different to that of healthy 
patients and, especially in the most advanced cases, has been severely depleted by 
aggressive antimicrobial treatments (Boyton et al., 2013) to remove pathogens 
causing exacerbations. As a consequence, they end up becoming colonised or 
infected with increasingly resistant strains or species which become increasingly 
difficult and, eventually, almost impossible to treat. The empty niches left behind 
after antibiotic regimes are propitious for opportunistic pathogens infections and this 
can lead to an additional vicious cycle in bronchiectasis. 
Therefore, proven that S. maltophilia is non-pathogenic or specific strains of S. 
maltophilia are non-pathogenic, these could be used as ‘artificial commensals’ to fill 
in the niches and prevent other more harmful bacteria from integrating the 
ecosystem, creating thereby a kind of ‘artificial commensal ecosystem’.  
Understandably, the main fear remains the potential risk for horizontal gene transfer 
of its wide range resistance to other pathogenic bacteria which is presumably the 
main reason for the tendency to treat patients at first isolation of S. maltophilia 
(Crossman et al., 2008). However, extensive studies on the resistance mechanisms 
have shown that most antibiotic resistance genes in S. maltophilia are not related to 
mobile genetic elements (Ryan et al., 2009). Further studies and a clinical trial 
looking at the ‘non-treatment’ of S. maltophilia should be carefully monitored and 
analysed before making any conclusion but are definitely worth considering.  
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5.4. Implication of S. maltophilia in disease progression 
A few observations from this study seem to suggest that S. maltophilia behaves 
quite similarly to the known pathogen P. aeruginosa, consistent with its initial 
classification as a Pseudomonas species.  
First, lung function and serological variables compared from 14-day IV-antibiotic 
courses where either S. maltophilia, P. aeruginosa and H. influenzae had been 
initially isolated, suggested that S. maltophilia was having an effect more similar to 
P. aeruginosa than H. influenzae in bronchiectasis patients. However, from the 
subsequent analyses, this could be rather attributed to a more efficient clearing of H. 
influenzae following IV-antibiotic treatment compared to P. aeruginosa and 
especially S. maltophilia which seems to be unaffected and even promoted following 
IV antibiotic treatment.  
On the other hand, inflammatory markers experiments looking at MPO and NE 
levels in sputum revealed a significant difference of elastase levels in sputum with S. 
maltophilia compared to that in sputum carrying MNF. This is also a known property 
of P. aeruginosa which elicits elastase activity in sputum as well as MPO  (Chalmers 
et al., 2012) and could be a sign of pathogenicity. 
However, there is insufficient evidence to confidently support or refute the 
pathogenicity of S. maltophilia and further experiments are needed: there seems to 
be no simple answer to this question but to do so, establishing the chronology 
between infection and disease progression will be essential. An in vitro experiment 
that would provide reliable evidence is to perform ELISA experiments looking at IL-8 
production of lung cells upon infection with S. maltophilia and compare them to that 
of uninfected cells and cells infected with a known pathogen such as P. aeruginosa, 
which is part of the future work planned.  
5.5. Environmental versus clinical 
The results from the experiments that aimed at comparing clinical strains with 
environmental ones suggest that antimicrobial susceptibility and virulence factors 
might not be very determining. Further genomics analysis might be required to 
establish more subtle differences and look at specific genes such as RNDs to 
potentially link certain types of strains with particular clinical outcomes of S. 
maltophilia infection (Crossman et al., 2008; Youenou et al., 2015). 
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5.6. Future work 
As mentioned above, experiments are currently on-going to provide further evidence 
regarding the pathogenicity of S. maltophilia. These would look in vitro at the 
inflammatory response of healthy cells upon infection of S. maltophilia which would 
help establish the chronology in the disease progression, removing any underlying 
inflammation purely due to bronchiectasis itself.  
However, in the scenario of evidence heading towards the refutation of its 
pathogenicity, controlled studies assessing its non-treatment should be considered. 
Alternatively, if its pathogenicity is confirmed, it will raise the urgent need for trials 
and disease-specific guidelines for antimicrobial treatment.  
Finally, an interesting aspect that arose following this study, is the potential 
implication of IV-antibiotic treatment as a risk factor for S. maltophilia infection. From 
the data analyses performed on patients on the IV-treated sub-group, IV-antibiotic 
therapy seemed to promote isolation of S. maltophilia. This could be either due to 
the antibiotics themselves clearing commensals and thus leaving empty niches 
behind as it was previously discussed, or it could be due to the IV mode of delivery 
itself: as an indwelling device, it could be a route of infection but in such case, one 
would expect accompanying skin infection at the level of the port which was not 
observed in our cohort. This definitely represents an interesting observation and 
deserves further examination as to whether nebulised administration of antibiotics is 
more efficient than intravenous.    
5.7. Limitations 
The main limitation of this study is the sample size. With a limited time-frame 
attempting to collect samples directly from patients wasn’t an easy task, especially 
as it seems like S. maltophilia being originally an environmental organism might be 
season dependent: samples took a while to reach a significant number sufficient to 
do any experiments with them.  
Similarly, isolation of S. maltophilia from environmental sources was low and a 
higher number of samples would have probably allowed for stronger evidence and 
better data.  
Furthermore, using retrospective data also meant being confronted with severely 
incomplete databases. For further studies, establishment of generic checklists of 
data to be systematically collected at clinic visits would significantly benefit the 
reliability of the database and facilitate retrospective research studies.   
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5.8. Concluding remarks 
The work presented here aimed at providing some characterisation of S. maltophilia 
in bronchiectasis and raise awareness of the importance of its accurate diagnosis 
among bronchiectasis patients as it seems that it has long been neglected and 
overlooked but appears to have an increasing importance in bronchiectasis.  
This work also highlights the need for a clear confirmation of the pathogenicity of the 
species in order to provide coherent guidelines for its subsequent treatment or non-
treatment after isolation from patients’ sputum.  
In the scenario of evidence leading towards the confirmation that S. maltophilia does 
not contribute to a deterioration of the patients’ lung condition, this study proposes a 
somewhat controversial use of S. maltophilia as an ‘artificial commensal’, using its 
intrinsic resistance enabling it to occupy the patients’ lung after aggressive 
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Annexe 1: Appearance of S. maltophilia on different selective media used for its isolation 
and identification 
S. maltophilia appearance 
on blood agar (BA): centre 
appears darker and outer 
ring is clearer with an olive-
like colour.  
S. maltophilia appearance 
on chocolate blood agar 
(CBA): big opaque 
colonies with a line 
showing centre and outer 
ring, brownish colour.  
S. maltophilia appearance 
on Pseudomonas isolation 
agar (PIA): centre appears 
darker and outer ring is 





Annexe 2: Figures of S. maltophilia strains tested for antimicrobial sensitivity using Etest 
strips of different antibiotics (Tobramycin, Imipenem, Doxycycline, TMP-SXT, Meropenem) 
Tobramycin (TM) Etest of a S.maltophilia 
strain: shows MIC of 0.5 µg/ml 
Imipenem (IP) Etest of a S.maltophilia strain: shows 
full resistance to Imipenem (MIC = 32 µg/ml) 
Doxycycline (DC) Etest of a S.maltophilia 
strain: shows MIC of 2 µg/ml 
TMP-SXT (TS) Etest of a S.maltophilia 
strain: shows MIC of 0.064 µg/ml 
Meropenem (MP) Etest of a S.maltophilia 
strain: shows MIC of 1 µg/ml 
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Annexe 3: Complementary data on matched patients for the S. maltophilia, P.aeruginosa 










Sex (Male) 64% 77% 36% 0.03 
Age 67 [63 – 74] 72 [64.5 – 73.25] 68 [63 – 71] 0.20 
BSI 8 [8 – 10] 11 [9.75 – 15] 11 [5.75 – 12] 0.03 
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Annexe 4: Complementary data on library of environmental and bronchiectasis S. 
maltophilia isolates 
 
IDENTIFICATION DATE OF COLLECTION ADDITIONAL INFORMATION 
PATIENT 1 (1) 11/02/2015 
Sample isolated prior to 14-day IV-
antibiotic course (at start of exacerbation) 
PATIENT 1 (2) 15/02/2015 
Sample isolated at day-14 following IV-
antibiotic course (at end of exacerbation) 
PATIENT 2 (1) 24/03/2014 
Sample isolated at the start of an 
exacerbation 
PATIENT 2 (2) 07/04/2014 
Sample isolated at the end of an 
exacerbation with antibiotic therapy 
PATIENT 3 (1) 02/04/2014 
Sample isolated from a stable sputum 
production 
PATIENT 3 (2) 08/03/2016 
Sample isolated from a stable sputum 
production 
PATIENT 4 (1) 19/02/2016 
Sample isolated at day-14 of a 14-day IV 
meropenem course 
PATIENT 4 (2) 25/02/2016 
Sample isolated at day-21 of a 14-day IV 
meropenem course 
PATIENT 5 (1) 17/03/2016 
Sample isolated at day-10 of a 8-day IV 
meropenem course 
PATIENT 5 (2) 21/04/2016 
Sample isolated at day-14 of a 8-day IV 
meropenem course 
PATIENT 5 (3) 28/04/2016 
Sample isolated at day-21 of a 8-day IV 
meropenem course 
PATIENT 6 12/07/2015 
Sample isolated at day-10 of a 14-day IV 
meropenem course 
PATIENT 7 07/08/2014 
Sample isolated at day-14 of a 8-day IV 
meropenem course 
PATIENT 8 24/03/2014 
Sample isolated from a stable sputum 
production 
PATIENT 9 25/03/2014 
Sample isolated from a stable sputum 
production 
PATIENT 10 12/02/2016 
Sample isolated at day-21 of IV 14-day 
meropenem course 
PATIENT 11 17/03/2016 
Sample isolated from a sputum produced 
by an inpatient with an exacerbation 
PATIENT 12 17/03/2016 
Sample isolated from a sputum produced 
by an inpatient with an exacerbation 
SALAD 1 09/02/2016 
Sample isolated from a green leaves salad 
sample 
SALAD 2 09/02/2016 Sample isolated from a spinach sample 
SALAD 3 24/02/2016 
Sample isolated from a mixed leaves salad 
sample 
SALAD 4 24/02/2016 Sample isolated from a watercress sample 
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Annexe 5: Complementary data on matched patients for the MNF/S.maltophilia comparison 





S. maltophilia  
(n=10) 
p-value 
Sex (Male) 43% 50% 1.00 
Age 69 [53 – 78] 74 [65.5 – 80] 0.27 






BA – Blood agar 
BHI – Brain Heart Infusion 
BSA – Bovine Serum Albumin 
CBA – Chocolate Blood agar 
CF – Cystic fibrosis 
DST [agar] – Diagnostic Sensitivity Test [agar] 
DTT – Diothiothreitol 
ELISA – Enzyme-linked immunosorbent assay 
HI – Haemophilus influenzae 
IL-8 – Interleukin 8 
IV [antibiotics] – Intravenous [antibiotics] 
MIC – Minimum inhibitory concentration 
MNF – Mixed Normal Flora 
MPO – Myeloperoxidase  
NA – Nutrient agar 
NB – Nutrient broth 
NE – Neutrophil elastase 
OD – Optical density 
PA – Pseudomonas aeruginosa 
PFGE – Pulsed-Field Gel Electrophoresis 
PIA – Pseudomonas Isolation agar 
QoL – Quality of Life 
SM –Stenotrophomonas maltophilia 
TBE [buffer] – Tris Borate EDTA [buffer] 
VIA – Vancomycin, Imipenem and Amphoterecin B 
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